Company Overview and News

China RMB 1.75 Trillion Automotive Finance Market, 2017-2021

2017-09-20 prnewswire
The "China Automotive Finance Industry Report, 2017-2021" report has been added to Research and Markets' offering.
Upvote Downvote

The Weather Company, an IBM Business, and UCAR Collaborate to Advance Weather Science Globally Through New Global Model Powered by IBM Supercomputing

2017-06-21 prnewswire
FRANKFURT, Germany, June 21, 2017 /PRNewswire/ -- At the International Supercomputing Conference in Frankfurt, The Weather Company, an IBM Business (NYSE: IBM), today announced a plan to help improve weather prediction globally via a new collaboration with the University Corporation for Atmospheric Research (UCAR) and the National Center for Atmospheric Research (NCAR), a federally funded research and development center for the atmosphere and Earth's geospace systems.
Upvote Downvote

Warburg Pincus dealmaker spots opportunities on Jakarta roadside

2017-03-15 theedgemarkets
(March 15): Warburg Pincus’s investment in the first billion-dollar Indonesian tech startup began with an American executive noticing green motorcycle helmets on the roads of Jakarta.
Upvote Downvote

CAR Inc. Heading Toward A Cliff

2017-01-09 seekingalpha
Rental car industry titan Hertz, as well as CAR Inc.’s Chairman Lu, have both sold almost all of their CAR Inc. shares prior to Q1 2016.
Upvote Downvote

Warburg Pincus Closes $2 Billion China Fund

2016-12-14 prnewswire
BEIJING, HONG KONG and NEW YORK, Dec. 14, 2016 /PRNewswire/ -- Warburg Pincus, a leading global private equity firm focused on growth investing, today announced it has successfully closed Warburg Pincus China, L.P. ("Warburg Pincus China").  Warburg Pincus China will be a $2 billion companion fund to Warburg Pincus Private Equity XII, L.P., a $13.4 billion global private equity fund that closed in late 2015.
Upvote Downvote

SAP's SuccessFactors HCM Solutions Gains Five New Clients

2016-09-28 zacks
Enterprise application software provider, SAP SE (SAP - Analyst Report) is on a roll, clinching multiple contracts for its human capital management ("HCM") solutions that help manage human resources (“HR”) on the cloud platform. The company’s proprietary cloud-based SAP SuccessFactors HCM Solutions has been significantly driving top-line growth. The recent client additions suggest this momentum is unlikely to fizzle out anytime soon.
Upvote Downvote

China's UCAR Listed on NEEQ, the First Chauffeured Car Service Listed in China

2016-07-25 prnewswire
BEIJING, July 25, 2016 /PRNewswire/ -- China's leading app-based chauffeured car services provider UCAR Inc. (Stock code: 838006) was listed on China's National Equities Exchange and Quotations (NEEQ) last Friday and closed at RMB 55.26, an increase of 13% from the initial offering, and a market value of RMB 41.8 billion.
Upvote Downvote

Ucar approved for NEEQ listing

2016-07-14 scmp
Ucar Inc, a car-hailing app launched by Hong Kong-listed China Auto Rental (Car Inc), the country’s leading car rental site, is going to become the first of its kind to be listed on China’s National Equities Exchange and Quotations (NEEQ), over-the-counter stock market.
Upvote Downvote

UCAR : chiffre d'affaires 2015

2016-02-25 prnewswire
BOULOGNE-BILLANCOURT, France, February 25, 2016 /PRNewswire/ -- L'inflexion stratégique se...
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

2018-04-25 - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...